trending Market Intelligence /marketintelligence/en/news-insights/trending/OTet1b__AWAwc25plI3zAg2 content esgSubNav
In This List

Synergy's Trulance gains FDA approval for chronic constipation

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Synergy's Trulance gains FDA approval for chronic constipation

The U.S. FDA approved Synergy Pharmaceuticals Inc.'s once-daily 3 milligram Trulance for adults with chronic idiopathic constipation.

The orally administered drug showed improved stool frequency and consistency in two studies compared to placebo. It is the first drug designed to replicate the function of uroguanylin, a gastrointestinal peptide that is thought to stimulate fluid secretion that results in a stool consistency associated with more regular bowel function, the company said in a news release.

Trulance will be available in the U.S. in the first quarter.

The company also said it completed two phase 3 trials for the drug to treat irritable bowel syndrome with constipation and plans to file a new drug application supplement later this quarter.